Partial compliance in schizophrenia and the impact on patient outcomes

Psychiatry Research

Volumn 161, Issue 2, 2008, Pages 235-247

  Llorca, Pierre Michel ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Antipsychotic; Atypical; Cognition; Insight; Schizophrenia; Therapeutic alliance

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSLIPIDEMIA; DYSPHORIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE TOLERANCE; HOSPITAL READMISSION; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; RELAPSE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; AWARENESS; HEALTH STATUS; HOSPITALIZATION; HUMANS; LONG-TERM CARE; MEDICATION ADHERENCE; PATIENT READMISSION; PROGNOSIS; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES;

EID: 54049144162     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2007.07.012     Document Type: Review

References (95)

1. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 65 (2004) 267-272
2. Aguglia E., De Vanna M., Onor M.L., and Ferrara D. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Progress in Neuro-psychopharmacology & Biological Psychiatry 26 (2002) 1229-1233
3. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156 (1999) 1686-1696
4. Aquila R., Weiden P.J., and Emanuel M. Compliance and the rehabilitation alliance. Journal of Clinical Psychiatry 60 Suppl 19 (1999) 23-27
5. Ascher-Svanum H., Faries D.E., Zhu B., Ernst F.R., Swartz M.S., and Swanson J.W. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry 67 (2006) 453-460
6. Awad A.G., and Hogan T.P. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica. Supplementum 380 (1994) 27-32
7. Ayuso-Gutierrez J.L., and del Rio Vega J.M. Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research 28 (1997) 199-206
8. Babiker I.E. Noncompliance in schizophrenia. Psychiatric Developments 4 (1986) 329-337
9. Bagnall A.M., Jones L., Ginnelly L., Lewis R., Glanville J., Gilbody S., Davies L., Torgerson D., and Kleijnen J. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment 7 (2003) 1-193
10. Baptista T., Zarate J., Joober R., Colasante C., Beaulieu S., Paez X., and Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Current Drug Targets 5 (2004) 279-299
11. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Kunz M., Chakos M., Cooper T.B., Horowitz T.L., and Lieberman J.A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry 159 (2002) 1018-1028
12. Blackwell B. Treatment adherence. British Journal of Psychiatry 129 (1976) 513-531
13. Brebion G., Bressan R.A., Amador X., Malaspina D., and Gorman J.M. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychological Medicine 34 (2004) 369-374
14. Burton S.C. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. Journal of Psychiatric Practice 11 (2005) 369-378
15. Byerly M., Fisher R., Rush A., Holland R., and Varghese F. A comparison of clinician vs. electronic monitoring of antipsychotic adherence in schizophrenia. Presented at the American College of Neuropsychopharmacology (ACNP) 41st Annual Meeting, December 8-12, 2002, San Juan, Puerto Rico (2002) 280 Abstract 169
16. Byerly M., Fisher R., Whatley K., Holland R., Varghese F., Carmody T., Magouirk B., and Rush A.J. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research 133 (2005) 129-133
17. Byerly M.J., Fisher R., Carmody T., and Rush A.J. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 66 (2005) 997-1001
18. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158 (2001) 518-526
19. Chue P., Llorca P., Duchesne I., Leal A., Rosillon D., and Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. The Journal of Applied Research 5 (2005) 266-274
20. Cramer J.A. Optimizing long-term patient compliance. Neurology 45 Suppl 1 (1995) S25-S28
21. Cramer J.A., and Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatric Services 49 (1998) 196-201
22. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., and Oulette V.L. How often is medication taken as prescribed? A novel assessment technique. Journal of the American Psychiatric Association 261 (1989) 3273-3277
23. Cuffel B.J., Alford J., Fischer E.P., and Owen R.R. Awareness of illness in schizophrenia and outpatient treatment adherence. Journal of Nervous and Mental Disease 184 (1996) 653-659
24. Dahl S.G. Pharmacokinetics of neuroleptic drugs and the utility of plasma level monitoring. Psychopharmacology Series 5 (1988) 34-46
25. Dam J. Insight in schizophrenia: a review. Nordic Journal of Psychiatry 60 (2006) 114-120
26. Davis J.M., Matalon L., Watanabe M.D., Blake L., and Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 47 (1994) 741-773
27. De Hert M., McKenzie K., and Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophrenia Research 47 (2001) 127-134
28. Diaz E., Levine H.B., Sullivan M.C., Sernyak M.J., Hawkins K.A., Cramer J.A., and Woods S.W. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. Journal of Psychiatry & Neuroscience 26 (2001) 325-329
29. Docherty J.P., Kozma C., Grogg A., and Lasser R. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Presented at the American College of Neuropsychopharmacology (ACNP) 41st Annual Meeting, December 8-12, 2002, San Juan, Puerto Rico (2002) 179 Abstract 154
30. Dolder C.R., Lacro J.P., Dunn L.B., and Jeste D.V. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. American Journal of Psychiatry 159 (2002) 103-108
31. Donohoe G., Owens N., O'Donnell C., Burke T., Moore L., Tobin A., and O'Callaghan E. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. European Psychiatry 16 (2001) 293-298
32. Eaddy M., Grogg A., and Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clinical Therapeutics 27 (2005) 263-272
33. Ereshefsky L., and Mascarenas C.A. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Journal of Clinical Psychiatry 64 (2003) 18-23
34. Ereshefsky L., Saklad S.R., Jann M.W., Davis C.M., Richards A., and Seidel D.R. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. Journal of Clinical Psychiatry 45 (1994) 50-59
35. Farmer K.C. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics 21 (1999) 1074-1090
36. Fleischhacker W.W., Meise U., Genther V., and Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scandinavica 89 suppl 382 (1994) 11-15
37. Fleischhacker W., Oehl M.A., and Hummer M. Factors influencing compliance in schizophrenia patients. Journal of Clinical Psychiatry 64 suppl 16 (2003) 10-13
38. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.M., Chrzanowski W., Martin S., and Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry 64 (2003) 1250-1257
39. Fleischhacker W.W., Rabinowitz J., Kemmler G., Eerdekens M., and Mehnert A. Perceived functioning and well-being and associated with psychiatric symptomatology in clinically stable schizophrenia patients treated with long-acting risperidone for 1 year. British Journal of Psychiatry 187 (2005) 131-136
40. Freudenreich O., Cather C., Evins A.E., Henderson D.C., and Goff D.C. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Journal of Clinical Psychiatry 65 (2004) 1372-1376
41. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
42. Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatrica Scandinavica 382 (1994) 28-32
43. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. International Clinical Psychopharmacology 9 Suppl 5 (1995) 17-20
44. Gharabawi G., Bossie C.A., Turkoz I., and Bouhours P. Insight in schizophrenia: results from a 12-month double-blind study. Presented at the Winter Workshop for Schizophrenia, 4-10 February, Davos, Switzerland (2006)
45. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., and Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs amongst Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161 (2004) 692-699
46. Glazer W.M. Review of incidence studies of tardive dyskinesia associated with atypical antipsychotics. Journal of Clinical Psychiatry 61 (2000) 15-20
47. Glick I.D., Lemmens P., and Vester-Blokland E. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. International Clinical Psychopharmacology 16 (2001) 265-274
48. Guthrie S.K. Clinical issues associated with maintenance treatment of patients with schizophrenia. American Journal of Health-System Pharmacy 59 (2002) S19-S24
49. Harvey P.D., Green M.F., McGurk S.R., and Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169 (2003) 404-411
50. Herings R.M., and Erkens J.A. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiology and Drug Safety 12 (2003) 423-424
51. Kampman O., and Lehtinen K. Compliance in psychoses. Acta Psychiatrica Scandinavica 100 (1999) 167-175
52. Kane J.M. Schizophrenia. New England Journal of Medicine 334 (1996) 34-41
53. Kane J.M. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal of Clinical Psychiatry 64 Suppl 16 (2003) 34-40
54. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S., Lesem M., and Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 160 (2003) 1125-1132
55. Keith S.J., and Kane J.M. Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal of Clinical Psychiatry 64 (2003) 1308-1315
56. Kemp R., Kirov G., Everitt B., Hayward P., and David A. Randomised controlled trial of compliance therapy. 18-month follow-up. British Journal of Psychiatry 172 (1998) 413-419
57. Lasser R., Bossie C., Gharabawi G., and Tuner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry 19 (2004) 219-225
58. Lasser R., Bossie C., Gharabawi G., and Baldessarini R. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. International Journal of Neuropsychopharmacology 8 (2005) 1-12
59. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
60. Lima J., Nazarian L., Charney E., and Lahti C. Compliance with short-term antimicrobial therapy: some techniques that help. Pediatrics 57 (1976) 383-386
61. Liu-Seifert H., Adams D.H., and Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 3 (2005) 21
62. Loffler W., Kilian R., Toumi M., and Angermeyer M.C. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 36 (2003) 105-112
63. Margolese H.C., Malchy L., Negrete J.C., Tempier R., and Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophrenia Research 67 (2004) 157-166
64. Mensin J., Boulanger L., Friedman M., Mackell J., and Lloyd J.R. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatric Services 54 (2003) 719-723
65. Mutsatsa S.H., Joyce E.M., Hutton S.B., Webb E., Gibbins H., Paul S., and Barnes T.R. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatrica Scandinavica 108 (2003) 439-446
66. Nasrallah H., Duchesne I., Mehnert A., and Janagap C. Health-related quality of life with schizophrenia during treatment with long-acting risperidone injection. Journal of Clinical Psychiatry 65 (2004) 531-536
67. Novak-Grubic V., and Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. European Psychiatry 17 (2002) 148-154
68. Oehl M., Hummer M., and Fleischhacker W.W. Compliance with antipsychotic treatment. Acta Psychiatrica Scandinavica. Supplementum 102 (2000) 83-86
69. Olfson M., Mechanic D., Hansell S., Boyer C.A., Walkup J., and Weiden P.J. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services 51 (2000) 216-222
70. Owen R.R., Fischer E.P., Booth B.M., and Cuffel B.J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services 47 (1996) 853-858
71. Pallanti S., Quercioli L., and Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Research 86 (1999) 239-249
72. Perkins D.O. Adherence to antipsychotic medications. Journal of Clinical Psychiatry 60 Suppl 21 (1999) 25-30
73. Perkins D.O. Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63 (2002) 1121-1128
74. Prouteau A., Verdoux H., Briand C., Lesage A., Lalonde P., Nicole L., Reinharz D., and Stip E. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophrenia Research 77 (2005) 343-353
75. Remington G., Kwon J., Collins A., Laporte D., Mann S., and Christensen B. The use of electronic monitoring (MEMS(R) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophrenia Research 90 1-3 (2007) 229-237
76. Rittmannsberger H., Pachinger T., Keppelmuller P., and Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatric Services 55 (2004) 174-179
77. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., and Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56 (1999) 241-247
78. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., and Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research 57 (2002) 209-219
79. Rosenberg K.P., Bleiberg K.L., Koscis J., and Gross C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. Journal of Sex & Marital Therapy 29 (2003) 289-296
80. Sackett D.L., Haynes R.B., Gibson E.S., Taylor D.W., Roberts R.S., and Johnson A.L. Patient compliance with antihypertensive regimens. Patient Counselling and Health Education 1 (1978) 18-21
81. Sajatovic M., Rosch D.S., Sivec H.J., Sultana D., Smith D.A., Alamir S., Buckley P., and Bingham C.R. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatric Services 53 (2002) 1319-1321
82. Schulz S.C., Thomson R., and Brecher M. The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophrenia Research 62 (2003) 1-12
83. Shobhana R., Begum R., Snehalatha C., Vijay V., and Ramachandran A. Patients' adherence to diabetes treatment. The Journal of the Association of Physicians of India 47 (1999) 1173-1175
84. Strunk R.C., Bender B., Young D.A., Sagel S., Glynn E., Caesar M., and Lawhon C. Predictors of protocol adherence in a pediatric asthma clinical trial. Journal of Allergy and Clinical Immunology 110 (2002) 596-602
85. Tattan T.M., and Creed F.H. Negative symptoms of schizophrenia and compliance with medication. Schizophrenia Bulletin 27 (2001) 149-155
86. Turner M., Eerdekens E., Jacko M., and Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International Clinical Psychopharmacology 19 (2004) 241-249
87. Valenstein M., Copeland L.A., Blow F.C., McCarthy J.F., Zeber J.E., Gillon L., Bingham C.R., and Stavenger T. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40 (2002) 630-639
88. van Os J., Bossie C., and Lasser R. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. International Clinical Psychopharmacology 19 (2004) 229-232
89. van Wanghe P., and Dequeker J. Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases. Annals of the Rheumatic Diseases 41 Suppl 1 (1982) 40-43
90. Walburn J., Gray R., Gournay K., Quraishi S., and David A.S. Systematic review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry 179 (2001) 300-307
91. Weiden P., and Zygmunt A. Medication noncompliance in schizophrenia. Part I. Assessment. Journal of Practical Psychiatry and Behavioural Health 3 (1997) 106-110
92. Weiden P.J., Kozma C., Grogg A., and Locklear J. Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatric Services 55 (2004) 886-891
93. Weiden P.J., Mackell J.A., and McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 66 (2004) 51-57
94. Wright E. Non-compliance - or how many aunts has Matilda?. The Lancet 342 (1993) 909-913
95. Wistedt B. How does the psychiatric patient feel about depot treatment, compulsion or help. Nordic Journal of Psychiatry 49 (1995) 41-46